Why the study?
What is the maximum-tolerated dose, optimal sequence, and antitumor efficacy of paclitaxel plus doxorubicin in women with untreated metastatic breast cancer?
Population
35 women with untreated metastatic breast cancer
Design
Cohort, Drug sequence was alternated in consecutive patients and in the first…
Follow-up
median 12 months (range 3 to 18)
Authors
Loading...
May warrant cardiac monitoring despite high activity; leaves open optimal dosing and sequencing pending randomized data.
What is the maximum-tolerated dose, optimal sequence, and antitumor efficacy of paclitaxel plus doxorubicin in women with untreated metastatic breast cancer?
The combination of paclitaxel and doxorubicin demonstrates high antitumor efficacy in metastatic breast cancer but is associated with a notable incidence of congestive heart failure.
Gianni et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: